Analystreport

Adaptimmune Therapeutics plc (NASDAQ: ADAP) had its price target lowered by analysts at Scotiabank from $3.15 to $1.40. They now have a "sector outperform" rating on the stock.

Adaptimmune Therapeutics plc - American Depositary Shares  (ADAP) 
Last adaptimmune therapeutics plc - american depositary shares earnings: 5/9 07:30 am Check Earnings Report